Study of AZD3152 intramuscular injection or intravenous infusion in Healthy Japanese Adult Participants

Exclusion Criteria

• - Known hypersensitivity to any component of the IMP.
• - History of allergic disease or reactions likely to be exacerbated by any component of the IMP.
• - Previous hypersensitivity, infusion related reaction or severe adverse reaction following administration of mAbs.
• - Fever above 38.0°C on day prior to or on day of randomisation/dosing.
• - AST, ALT or serum creatinine above ULN; bilirubin and ALP >1.5 × ULN.
• - Any vaccination except for COVID-19 vaccine (e.g., inactivated influenzae vaccine) planned.
• - SARS CoV-2 or COVID-19:
• Receipt of a COVID-19 vaccine within 3 months.
• COVID-19 infection within 3 months prior.